RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1110
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained an Outperform rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and increased the price target from $1076 to $1110.
February 05, 2024 | 3:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reaffirmed its Outperform rating on Regeneron Pharmaceuticals and raised its price target from $1076 to $1110.
The increase in price target by RBC Capital suggests a strong confidence in Regeneron Pharmaceuticals' future performance. This endorsement from a reputable analyst is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100